Should the new EASL-EASD-EASO Clinical Practice Guidelines on MASLD recommend pioglitazone as a MASH-targeted pharmacotherapy?
J Hepatol
.
2025 Jan;82(1):e21-e22.
doi: 10.1016/j.jhep.2024.06.034.
Epub 2024 Jul 4.
Authors
Wellington S Silva Júnior
1
,
Andrei C Sposito
2
,
Amélio Godoy-Matos
3
Affiliations
1
Universidade Federal do Maranhão (UFMA), Sao Luis, MA, Brazil. Electronic address:
[email protected]
.
2
Universidade Estadual de Campinas (Unicamp), Campinas, SP, Brazil.
3
Instituto Estadual de Diabetes e Endocrinologia do Rio de Janeiro (IEDE), Rio de Janeiro, RJ, Brazil.
PMID:
38971532
DOI:
10.1016/j.jhep.2024.06.034
No abstract available
Publication types
Letter